Avanos Medical Inc (AVNS)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -61,800 | -55,400 | -36,000 | 44,600 | 50,500 | 45,100 | -5,900 | 20,100 | 6,300 | -54,200 | 400 | -41,100 | -29,000 | 13,900 | -16,900 | -21,900 | -45,900 | -42,000 | -26,300 | 17,000 |
| Total stockholders’ equity | US$ in thousands | 1,236,300 | 1,222,100 | 1,234,800 | 1,298,700 | 1,291,200 | 1,263,500 | 1,259,000 | 1,262,800 | 1,270,600 | 1,267,100 | 1,301,700 | 1,257,400 | 1,262,100 | 1,289,900 | 1,261,600 | 1,256,500 | 1,272,600 | 1,266,900 | 1,276,900 | 1,280,100 |
| ROE | -5.00% | -4.53% | -2.92% | 3.43% | 3.91% | 3.57% | -0.47% | 1.59% | 0.50% | -4.28% | 0.03% | -3.27% | -2.30% | 1.08% | -1.34% | -1.74% | -3.61% | -3.32% | -2.06% | 1.33% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-61,800K ÷ $1,236,300K
= -5.00%
The return on equity (ROE) of Avanos Medical Inc has shown fluctuations over the past eight quarters. The ROE ranged from -5.00% to 3.91% during this period.
The company experienced negative ROE in Q4 2023 and Q3 2023, indicating that it generated a net loss or its net income was insufficient to cover shareholders' equity during these quarters. This may raise concerns about the profitability and efficiency of the company in utilizing shareholders' investments.
The positive ROE in Q1 2023, Q4 2022, and Q2 2022 suggests that the company was able to generate a profit relative to its shareholders' equity during those periods. However, the profitability levels were relatively low, ranging from 1.48% to 3.91%.
Overall, the fluctuating ROE trend indicates varying levels of profitability and efficiency in leveraging shareholders' equity by Avanos Medical Inc. It may be important for stakeholders to assess the reasons behind the negative ROE quarters and monitor the company's efforts to improve its profitability, operational efficiency, and financial performance.
Peer comparison
Dec 31, 2023